Comparative Pharmacology
Head-to-head clinical analysis: LOMUSTINE versus VALCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMUSTINE versus VALCHLOR.
LOMUSTINE vs VALCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibits DNA synthesis, and produces interstrand crosslinks via chloroethyl carbonium ion formation. Also has carbamoylating activity.
Valchlor (mechlorethamine) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, leading to inhibition of DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
130 mg/m² orally as a single dose every 6 weeks; subsequent doses adjusted based on hematologic response.
Topical: Apply 0.016% mechlorethamine gel to affected areas once daily.
None Documented
None Documented
Biphasic: initial half-life ~6 hours; terminal half-life ~16-48 hours (mean 24 hours). Metabolites have prolonged half-life up to 72 hours. Clinical context: accumulation with repeated dosing, requiring 6-week intervals.
Clinical Note
moderateLomustine + Digoxin
"Lomustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLomustine + Digitoxin
"Lomustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLomustine + Deslanoside
"Lomustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLomustine + Acetyldigitoxin
"Lomustine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is approximately 24 hours after topical application, supporting daily dosing. Systemic half-life may be prolonged in patients with hepatic impairment.
Renal excretion approximately 50% (as metabolites), biliary/fecal excretion approximately 20%; remainder unaccounted, likely metabolized.
Following topical application, VALCHLOR (mechlorethamine) is systemically absorbed; approximately <10% is excreted unchanged in urine. The majority of the dose is eliminated via metabolism and biliary/fecal routes, with ~50% of a systemic dose recovered in feces as metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent